|
For joke tellers and Depomed, it's all about the delivery. The drug company makes proprietary drug therapies using its patented delivery technology AcuForm, an extended-release technology that stretches out the time a pill stays in the stomach, thus reducing the number of necessary doses and possibly lessening side effects. Depomed's internal development efforts have yielded two FDA-approved products: Glumetza, an extended-release formulation of common diabetes drug metformin, and ProQuin XR, a treatment for urinary tract infections. King Pharmaceuticals, which had marketed Glumetza in the US, terminated its promotion efforts in 2007.
|
| | | Contact Information | |
Address: |
1360 O'Brien Dr.
Menlo Park, CA 94025-1436
| | Phone: | 650-462-5900 | | Fax: | 650-462-9993 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 34.80 M | | Revenue Growth (1 yr): | (-46.90%) | | Employees (2008): | 81 | | Employee Growth (1 yr): | 11.00% |
|
|
Key People
| | • |
Chairman:
Peter D. Staple
| | • |
President, CEO, and Director:
Carl A. Pelzel
| | • |
VP Finance:
Tammy L. Cameron
|
|
|
